Juncai Jiang filed an initial disclosure upon appointment as director of SUNSHINE PHARMA (06887) on June 18, 2026; long position ratio 0.07%. This statutory filing is not a direct on-market dealing.
Prior to the acquisition, Juncai Jiang's long position in SUNSHINE PHARMA was 0 shares, representing 0%; following the acquisition, the holding changed to 215,504 shares, with the long position ratio rising to 0.07%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments